Massimo Di Maio, PhD, University of Turin, Turin, Italy, explains the rationale and study design of the Phase II URO-12 trial (NCT03945084) which investigated the use of niraparib as maintenance therapy for patients with advanced urothelial carcinoma who have undergone first-line platinum-based chemotherapy. After 4-6 rounds of platinum-based chemotherapy, patients in the experimental arm received niraparib until either disease progression or unacceptable levels of toxicity were reached. Patients in the control arm received best supportive care as maintenance therapy. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.